TapewireFind a company

person · Reporting owner

Dube Eric M

Disclosed activity across 2 companies

Tapewire entity
49360
SEC CIK
0001763494

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
OnKure Therapeutics, Inc.RPHM · Entity 6550DirectorJune 06, 2023June 08, 2023
Travere Therapeutics, Inc.TVTX · Entity 1562Director · CHIEF EXECUTIVE OFFICERSeptember 15, 2026September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

OnKure Therapeutics, Inc.

Report date June 06, 2023 · Filed June 08, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05Direct17,500 Reported balance After 2023-06-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500

F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Travere Therapeutics, Inc.

Report date September 15, 2026 · Filed September 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect432,886 Ending reported balance After 2026-09-17 transaction · row 11
11 source rows · reconciled sequence

Row 1 · 2026-09-15 · Exercise / conversion · Acquired 95,666 · Balance 528,552

Row 2 · 2026-09-15 · Sale · Disposed 63,498 · Balance 465,054

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 3 · 2026-09-15 · Sale · Disposed 28,796 · Balance 436,258

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 4 · 2026-09-15 · Sale · Disposed 3,102 · Balance 433,156

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F4: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 5 · 2026-09-15 · Sale · Disposed 270 · Balance 432,886

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Row 6 · 2026-09-16 · Exercise / conversion · Acquired 195,841 · Balance 628,727

Row 7 · 2026-09-16 · Sale · Disposed 99,716 · Balance 529,011

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F5: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 8 · 2026-09-16 · Sale · Disposed 96,125 · Balance 432,886

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F6: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 9 · 2026-09-17 · Exercise / conversion · Acquired 108,493 · Balance 541,379

Row 10 · 2026-09-17 · Sale · Disposed 101,691 · Balance 439,688

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F7: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Row 11 · 2026-09-17 · Sale · Disposed 6,802 · Balance 432,886

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F8: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04Direct304,334 Reported balance After 2026-09-15 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2026-09-15 · Exercise / conversion · Disposed 95,666 · Balance 304,334

F9: The stock option is fully vested and exercisable.

Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04Direct108,493 Reported balance After 2026-09-16 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2026-09-16 · Exercise / conversion · Disposed 195,841 · Balance 108,493

F9: The stock option is fully vested and exercisable.

Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04Direct0 Reported balance After 2026-09-17 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2026-09-17 · Exercise / conversion · Disposed 108,493 · Balance 0

F9: The stock option is fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F3: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F4: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F5: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F6: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F7: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F8: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

F9: The stock option is fully vested and exercisable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 17, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 108,493 $0.00 Strike: $23.34 $0.00
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · derivative · entry 14

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 108,493 shares

Expires 2029-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
September 17, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 6,802 $64.95 $441,795.34
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 11

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F8 · price: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
September 17, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 101,691 $64.59 $6,567,875.94
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 10

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 439,688

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F7 · price: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
September 17, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 108,493 $23.34 $2,532,226.62
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 9

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 541,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 195,841 $0.00 Strike: $23.34 $0.00
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · derivative · entry 13

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,493

Underlying: Common Stock · 195,841 shares

Expires 2029-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 96,125 $63.64 $6,117,289.26
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 8

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F6 · price: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 99,716 $63.26 $6,307,964.36
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 7

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 529,011

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F5 · price: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
September 16, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 195,841 $23.34 $4,570,928.94
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 6

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 628,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 15, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 95,666 $0.00 Strike: $23.34 $0.00
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · derivative · entry 12

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 304,334

Underlying: Common Stock · 95,666 shares

Expires 2029-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
September 15, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 270 $65.31 $17,633.70
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 5

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Read SEC document
September 15, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 3,102 $63.64 $197,421.83
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 433,156

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F4 · price: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
September 15, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 28,796 $62.66 $1,804,222.02
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 436,258

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3 · price: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
September 15, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 63,498 $61.99 $3,936,526.76
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 465,054

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
September 15, 2026 Filed Sep 18, 2026 01:31 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 95,666 $23.34 $2,232,844.44
Disclosure

SEC source: 0001763494-26-000007 · form4-09182026_010928.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 528,552

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 06, 2026 Filed May 7, 2026 00:00 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 22,500 $43.95 $988,875.00
Disclosure

SEC source: 0001763494-26-000006 · form4-05062026_080504.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Read SEC document
May 04, 2026 Filed May 7, 2026 00:00 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionPerformance-based restricted stock units · Derivative 22,500 $0.00 $0.00
Disclosure

SEC source: 0001763494-26-000006 · form4-05062026_080504.xml · derivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

Read SEC document
May 04, 2026 Filed May 7, 2026 00:00 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantPerformance-based restricted stock units · Derivative 45,000 $0.00 $0.00
Disclosure

SEC source: 0001763494-26-000006 · form4-05062026_080504.xml · derivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions.

F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

F1 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

Read SEC document
May 04, 2026 Filed May 7, 2026 00:00 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 22,500 $0.00 $0.00
Disclosure

SEC source: 0001763494-26-000006 · form4-05062026_080504.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 455,386

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 45,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion.

Read SEC document
April 15, 2026 Filed Apr 16, 2026 01:48 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 20 $42.66 $853.20
Disclosure

SEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Read SEC document
April 15, 2026 Filed Apr 16, 2026 01:48 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 7,165 $41.75 $299,138.75
Disclosure

SEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,906

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F4 · price: The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
April 15, 2026 Filed Apr 16, 2026 01:48 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 56,815 $41.01 $2,329,983.15
Disclosure

SEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 440,071

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
April 13, 2026 Filed Apr 16, 2026 01:48 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantCommon Stock 64,000 $0.00 $0.00
Disclosure

SEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 496,886

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

Read SEC document
April 01, 2026 Filed Apr 2, 2026 21:55 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 60,000 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · derivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
April 01, 2026 Filed Apr 2, 2026 21:55 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 25,098 $31.46 $789,583.08
Disclosure

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.

F3 · price: The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
April 01, 2026 Filed Apr 2, 2026 21:55 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 34,902 $30.55 $1,066,256.10
Disclosure

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 457,984

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.

F2 · price: The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
April 01, 2026 Filed Apr 2, 2026 21:55 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 60,000 $15.46 $927,600.00
Disclosure

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 492,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 60,000 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-26-000003 · form4-02242026_040201.xml · derivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 60,000 $30.10 $1,805,766.00
Disclosure

SEC source: 0001763494-26-000003 · form4-02242026_040201.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $30.0961, and the range of prices were between $30.00 and $30.325. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 21:05 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 60,000 $15.46 $927,600.00
Disclosure

SEC source: 0001763494-26-000003 · form4-02242026_040201.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 492,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 03, 2026 Filed Feb 4, 2026 02:30 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 33,635 $32.70 $1,099,864.50
Disclosure

SEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4 · price: The weighted average sale price for the transaction reported was $32.70, and the range of prices were between $32.5248 and $32.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
February 03, 2026 Filed Feb 4, 2026 02:30 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 66,452 $32.06 $2,130,451.12
Disclosure

SEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 466,521

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $32.06, and the range of prices were between $31.52 and $32.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
January 31, 2026 Filed Feb 4, 2026 02:30 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantEmployee stock option (right to buy) · Derivative 303,600 $0.00 Strike: $33.10 $0.00
Disclosure

SEC source: 0001763494-26-000002 · form4-02032026_090212.xml · derivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 303,600

Underlying: Common Stock · 303,600 shares

Expires 2036-01-31

F5 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
January 31, 2026 Filed Feb 4, 2026 02:30 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 GrantCommon Stock 113,800 $0.00 $0.00
Disclosure

SEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 532,973

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 01:25 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 51,865 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-26-000001 · form4-01282026_010144.xml · derivative · entry 6

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 51,865 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 01:25 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 51,865 $30.10 $1,560,980.91
Disclosure

SEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3 · price: The weighted average sale price for the transaction reported was $30.097, and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 01:25 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 51,865 $15.46 $801,832.90
Disclosure

SEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 471,038

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 23, 2026 Filed Jan 28, 2026 01:25 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 8,135 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-26-000001 · form4-01282026_010144.xml · derivative · entry 5

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,865

Underlying: Common Stock · 8,135 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
January 23, 2026 Filed Jan 28, 2026 01:25 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 8,135 $30.01 $244,153.31
Disclosure

SEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $30.0127, and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
January 23, 2026 Filed Jan 28, 2026 01:25 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 8,135 $15.46 $125,767.10
Disclosure

SEC source: 0001763494-26-000001 · form4-01282026_010144.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 427,308

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 29, 2025 Filed Oct 30, 2025 20:45 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 27,128 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · derivative · entry 6

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 27,128 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
October 29, 2025 Filed Oct 30, 2025 20:45 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 27,128 $30.12 $817,073.66
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F3 · price: The weighted average sale price for the transaction reported was $30.1192, and the range of prices were between $30.00 and $30.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
October 29, 2025 Filed Oct 30, 2025 20:45 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 27,128 $15.46 $419,398.88
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 446,301

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:45 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionEmployee stock option (right to buy) · Derivative 92,872 $0.00 Strike: $15.46 $0.00
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · derivative · entry 5

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,128

Underlying: Common Stock · 92,872 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:45 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 92,872 $30.38 $2,821,358.49
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $30.379, and the range of prices were between $30.00 and $30.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:45 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 92,872 $15.46 $1,435,801.12
Disclosure

SEC source: 0001763494-25-000005 · form4-10302025_041004.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 512,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 05, 2025 Filed May 6, 2025 01:53 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 18,924 $21.05 $398,350.20
Disclosure

SEC source: 0001415889-25-012058 · form4-05062025_010542.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:53 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionPerformance-based restricted stock units · Derivative 18,924 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-012058 · form4-05062025_010542.xml · derivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,924

Underlying: Common Stock · 18,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

Read SEC document
May 02, 2025 Filed May 6, 2025 01:53 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 Exercise / conversionCommon Stock 18,924 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-25-012058 · form4-05062025_010542.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 438,097

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 37,848 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.

F2 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 02:23 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 11,375 $24.04 $273,455.00
Disclosure

SEC source: 0001415889-25-003820 · form4-02132025_020239.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 419,173

F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 01:30 UTC Travere Therapeutics, Inc. TVTX · Entity 1562 SaleCommon Stock 50,691 $20.21 $1,024,343.45
Disclosure

SEC source: 0001415889-25-003065 · form4-02042025_080216.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 430,548

F2 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $20.2076, and the range of prices were between $19.76 and $20.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.